Journal of Internal Medicine Concepts & Practice >

2024 , Vol. 19 >Issue 05: 318 - 321

DOI: https://doi.org/10.16138/j.1673-6087.2024.05.06

Case report

Invasive pulmonary aspergillosis secondary to immunosuppressive therapy in nephrotic syndrome: a case report

  • RUAN Yilin ,
  • XU Tian ,
  • FENG Xiaobei ,
  • XU Jing ,
  • SHI Hao ,
  • REN Hong
Expand
  • Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2023-11-13

  Online published: 2025-01-16

Fold

Abstract

A 61-year-old male with a one-year history of membranous nephropathy was placed on combined therapy of glucocorticoids and rituximab. On the 12th day of treatment, the patient developed high fever, accompanied by mild cough and night sweats. Chest CT revealed multiple nodules and patchy opacities in both lungs. Bronchoalveolar lavage fluid (BALF) analysis using next-generation sequencing (NGS) identifed Aspergillus infection, and two consecutive β-D-glucan tests were positive. The clinical diagnosis of invasive pulmonary aspergillosis (IPA) was established. The patient received intravenous voriconazole for six months. Follow-up chest CT showed significant absorption of pulmonary lesions. The treatment regimen led to recovery of the patient and achieved partial remission of nephrotic.

Key words： Membranous nephropathy; Invasive pulmonary aspergillosis; Immunosuppressive therapy; Rituximab; Next-generation sequencing

Cite this article

RUAN Yilin , XU Tian , FENG Xiaobei , XU Jing , SHI Hao , REN Hong . Invasive pulmonary aspergillosis secondary to immunosuppressive therapy in nephrotic syndrome: a case report[J]. Journal of Internal Medicine Concepts & Practice, 2024 , 19(05) : 318 -321 . DOI: 10.16138/j.1673-6087.2024.05.06

References

[1] Hull RP, Goldsmith DJA. Nephrotic syndrome in adults[J]. BMJ, 2008, 336(7654):1185-1189.
[2] Li J, Zhang Q, Su B. Clinical characteristics and risk factors of severe infections in hospitalized adult patients with primary nephrotic syndrome[J]. J Int Med Res, 2017, 45(6):2139-2145.
[3] van den Brand JAJG, Ruggenenti P, Chianca A, et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 2017, 28(9):2729-2737.
[4] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S):S1-S276.
[5] Debiec H, Ronco P. Immunopathogenesis of membranous nephropathy[J]. Semin Immunopathol, 2014, 36(4):381-397.
[6] Teisseyre M, Cremoni M, Boyer-suavet S, et al. Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy[J]. Front Immunol, 2022, 13:859419.
[7] Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy[J]. N Engl J Med, 2019, 381(1):36-46.
[8] Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance[J]. Oncogene, 2003, 22(47):7359-7368.
[9] Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 2012, 23(8):1416-1425.
[10] Del Vecchio L, Allinovi M, Rocco P, et al. Rituximab therapy for adults with nephrotic syndromes: standard schedules or B cell-targeted therapy?[J]. J Clin Med, 2021, 10(24):5847.
[11] Zilberberg MD, Harrington R, Spalding JR, et al. Burden of hospitalizations over time with invasive aspergillosis in the United States, 2004-2013[J]. BMC Public Health, 2019, 19(1):591.
[12] Thompson GR, Young J-AH. Aspergillus infections[J]. N Engl J Med, 2021, 385(16):1496-1509.
[13] Liu Z, Li Y, Tian X, et al. Airway-invasion-associated pulmonary computed tomography presentations characteristic of invasive pulmonary aspergillosis in non-immunocompromised adults: a national multicenter retrospective survey in China[J]. Respir Res, 2020, 21(1):173.
[14] 冯珍, 董春霞, 郭岚, 等. 肾病综合征应用免疫抑制剂治疗并发肺及皮肤隐球菌感染一例报道并文献复习[J]. 中国全科医学, 2019, 22(17):2130-2135.
[15] Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium[J]. Clin Infect Dis, 2020, 71(6):1367-1376.
[16] Desoubeaux G, Bailly é, Chandenier J. Diagnosis of invasive pulmonary aspergillosis: updates and recommendations[J]. Med Mal Infect, 2014, 44(3):89-101.
[17] Lamoth F. Galactomannan and 1,3-β-d-glucan Testing for the diagnosis of invasive aspergillosis[J]. J Fungi (Basel), 2016, 2(3):22.
[18] 唐晓丹, 李光辉. 2016年美国感染病学会曲霉病诊断处理实践指南[J]. 中国感染与化疗杂志, 2017, 17(4):456-462.
[19] 中国医师协会血液科医师分会, 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第六次修订版)[J]. 中华内科杂志, 2020, 59(10):754-763.
Options
Outlines

/

〈 〉